Shore Capital Reiterates “Buy” Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities research analysts at Shore Capital in a research note issued to investors on Thursday, MarketBeat.com reports.

A number of other equities analysts have also recently issued reports on GSK. JPMorgan Chase & Co. increased their target price on GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a report on Friday, November 7th. Berenberg Bank increased their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Finally, Jefferies Financial Group lifted their price objective on GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a report on Monday, November 3rd. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, GSK currently has an average rating of “Hold” and an average target price of GBX 1,762.

GSK Price Performance

LON:GSK opened at GBX 1,886 on Thursday. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a 50-day moving average of GBX 1,809.73 and a 200-day moving average of GBX 1,600.65. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 1,909.73. The company has a market capitalization of £76.08 billion, a price-to-earnings ratio of 14.18, a PEG ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds bought 1,650 shares of the stock in a transaction dated Monday, December 22nd. The stock was bought at an average cost of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker purchased 441 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was acquired at an average cost of GBX 1,809 per share, with a total value of £7,977.69. 0.20% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.